WASHINGTON — Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want Congress to take a deeper look at how Biogen’s controversial and pricey new Alzheimer’s drug, Aduhelm, will affect the Medicare program, they wrote in a letter Wednesday.
The bipartisan duo is pressing the Senate Finance Committee to take on “the vexing new questions and challenges that approval raises for the Medicare program and other health programs” the panel oversees, they wrote.